Phase II Study of Sunitinib Following Hepatic Transarterial Embolization for Metastatic Neuroendocrine Tumors

#211

Introduction: Hepatic transarterial embolization is often recommended for patients with liver-predominant metastatic NETs. Antiangiogenic therapy following embolization may delay tumor revascularization.

Aim(s): To assess radiographic response rates and progression-free survival associated with hepatic artery embolization followed by sunitinib.

Materials and methods: Patients with metastatic NETs to the liver underwent a series of selective bland arterial embolizations followed by sunitinib (one week after each embolization until disease progression or a maximum of eight cycles).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Strosberg J, Cheema A, Campos T, Kvols L,

Keywords: transarterial embolization, sunitinib, progression-free survival,

To read the full abstract, please log into your ENETS Member account.